Potential relevance of changes in haematocrit to changes in lipid parameters with empagliflozin in patients with type 2 diabetes

Objective: Empagliflozin consistently reduces HbA1c in patients with type 2 diabetes (T2DM) and changes in lipids have been observed. To test our hypothesis that changes in lipids could be partly due to haemoconcentration resulting from increased urinary volume and subsequent volume contraction with empagliflozin, we analysed potential contributions of changes in haematocrit, a marker of changes in plasma volume, to changes in lipids. Methods: Using pooled data from four 24-week, Phase III, randomised trials in patients with T2DM who received placebo, empagliflozin 10 mg or empagliflozin 25 mg for 24 weeks as mo…